Vistagen Therapeutics, Inc. (VTGN) Form 10-K — Jun 15, 2026
Vistagen Therapeutics is a clinical-stage biopharmaceutical company developing intranasal pherine product candidates for neurological disorders. Its lead asset, fasedienol, is in a Phase 3 program for social anxiety disorder, though the PALISADE-3 trial failed to achieve its primary endpoint in late 2025 and results for PALISADE-4 are expected in the second quarter of 2026. The company is advancing other candidates including itruvone for major depressive disorder and refisolone for menopausal hot flashes, for which it received a FDA Study May Proceed letter in April 2026.
Key figures
- Shares Outstanding
- 41032453
- Full Time Employees
- 41
- Affa Med Upfront Payment
- $5.0 million
- Fuji Pharma Purchase Price
- $1.5 million
- Market Value Non Affiliates
- $137.7 million
- Workforce Reduction Percent
- 20%
- Fasedienol Phase3 Subjects Exposed
- >1500
Price after filing
Close on the filing date to close N calendar days later (from $0.57). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.